A Study of AAVB-039 for Stargardt Disease
This study is testing a treatment called AAVB-039 for people with Stargardt disease (STGD1). Stargardt disease is an inherited eye condition that causes progressive vision loss. Researchers want to see how safe AAVB-039 is and if people can tolerate it after a single injection into the eye. They will also look for early signs of how well it works. You might be able to join if you are between 8 and 55 years old and have a genetic diagnosis of Stargardt disease due to a specific gene change (ABCA4 mutation). The study plans to enroll about 75 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll about 75 participants. It will evaluate a single treatment of AAVB-039.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for treatment-related side effects for up to 60 months (5 years) after receiving AAVB-039.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
At a glance
Conditions
Where it's being run
9 sites across 7 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- To measure the number and severity of treatment related adverse events following treatment with AAVB-0390-60 months